Poseida Price To Sales Ratio from 2010 to 2024
| PSTX Stock | USD 9.31 0.02 0.21% |
Price To Sales Ratio | First Reported 2010-12-31 | Previous Quarter 4.68327469 | Current Value 4.45 | Quarterly Volatility 6.2 K |
Check Poseida Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Poseida Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 9.1 M, Income Tax Expense of 112.3 K or Tax Provision of 112.3 K, as well as many indicators such as Price To Sales Ratio of 4.45, Dividend Yield of 0.0 or PTB Ratio of 4.84. Poseida financial statements analysis is a perfect complement when working with Poseida Therapeutics Valuation or Volatility modules.
Poseida | Price To Sales Ratio |
Latest Poseida Therapeutics' Price To Sales Ratio Growth Pattern
Below is the plot of the Price To Sales Ratio of Poseida Therapeutics over the last few years. Price to Sales Ratio is figured by comparing Poseida Therapeutics stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Poseida Therapeutics sales, a figure that is much harder to manipulate than other Poseida Therapeutics multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. It is a valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period. Poseida Therapeutics' Price To Sales Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Poseida Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 6.03 X | 10 Years Trend |
|
Price To Sales Ratio |
| Timeline |
Poseida Price To Sales Ratio Regression Statistics
| Arithmetic Mean | 3,672 | |
| Geometric Mean | 196.78 | |
| Coefficient Of Variation | 167.97 | |
| Mean Deviation | 5,270 | |
| Median | 93.21 | |
| Standard Deviation | 6,169 | |
| Sample Variance | 38.1M | |
| Range | 13.6K | |
| R-Value | 0.34 | |
| Mean Square Error | 36.1M | |
| R-Squared | 0.12 | |
| Significance | 0.21 | |
| Slope | 475.04 | |
| Total Sum of Squares | 532.7M |
Poseida Price To Sales Ratio History
About Poseida Therapeutics Financial Statements
Poseida Therapeutics investors use historical fundamental indicators, such as Poseida Therapeutics' Price To Sales Ratio, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Poseida Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Price To Sales Ratio | 4.68 | 4.45 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Poseida Stock Analysis
When running Poseida Therapeutics' price analysis, check to measure Poseida Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Poseida Therapeutics is operating at the current time. Most of Poseida Therapeutics' value examination focuses on studying past and present price action to predict the probability of Poseida Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Poseida Therapeutics' price. Additionally, you may evaluate how the addition of Poseida Therapeutics to your portfolios can decrease your overall portfolio volatility.